The use of dendritic cells in cancer therapy

Lancet Oncology

Volumn 2, Issue 6, 2001, Pages 343-353

  Jefford, M ^a,c   Maraskovsky, E ^a   Cebon, J ^b   Davis, I D ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Stewardson Family Trust   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGICAL ADJUVANT; TUMOR ANTIGEN;

CLINICAL TRIAL; DENDRITIC CELL; FORECASTING; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; LYMPHOMA; MALE; MELANOMA; MULTIPLE MYELOMA; NEOPLASM; PHYSIOLOGY; PROSTATE TUMOR; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, NEOPLASM; CARCINOMA, RENAL CELL; CLINICAL TRIALS; DENDRITIC CELLS; FORECASTING; HUMANS; KIDNEY NEOPLASMS; LYMPHOMA; MALE; MELANOMA; MULTIPLE MYELOMA; NEOPLASMS; PROSTATIC NEOPLASMS;

EID: 0039782448     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(00)00389-2     Document Type: Review

References (75)

1. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature. 392:1998;245-252.
2. Hart D.N. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood. 90:1997;3245-3287.
3. Shortman K., Caux C. Dendritic cell development: multiple pathways to nature's adjuvants. Stem Cells. 15:1997;409-419.
4. Mortarini R., Anichini A., Di Nicola M., et al. Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. Cancer Res. 57:1997;5534-5541.
5. Rissoan M.C., Soumelis V., Kadowaki N., et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science. 283:1999;1183-1186.
6. Steinbrink K., Wolfl M., Jonuleit H., et al. Induction of tolerance by IL-10-treated dendritic cells. J Immunol. 159:1997;4772-4780.
7. Siena S., Di Nicola M., Bregni M., et al. Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Exp Hematol. 23:1995;1463-1471.
8. Bernhard H., Disis M.L., Heimfeld S., et al. Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res. 55:1995;1099-1104.
9. Sato K., Nagayama H., Takahashi T.A. Generation of dendritic cells from fresh and frozen cord blood CD34+ cells. Cryobiology. 37:1998;362-371.
10. Caux C., Vanbervliet B., Massacrier C., et al. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha. J Exp Med. 184:1996;695-706.
11. Luft T., Pang K.C., Thomas E., et al. A serum-free culture model for studying the differentiation of human dendritic cells from adult CD34+ progenitor cells. Exp Hematol. 26:1998;489-500.
12. Jaksits S., Kriehuber E., Charbonnier A.S., et al. CD34+ cell-derived CD14+ precursor cells develop into Langerhans cells in a TGF-beta 1-dependent manner. J Immunol. 163:1999;4869-4877.
13. Strobl H., Riedl E., Scheinecker C., et al. TGF-beta 1 promotes in vitro development of dendritic cells from CD34+ hemopoietic progenitors. J Immunol. 157:1996;1499-1507.
14. Romani N., Gruner S., Brang D., et al. Proliferating dendritic cell progenitors in human blood. J Exp Med. 180:1994;83-93.
15. O'Doherty U., Peng M., Gezelter S., et al. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology. 82:1994;487-493.
16. Maraskovsky E., Daro E., Roux E., et al. In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood. 96:2000;878-884.
17. Lynch D.H., Andreasen A., Maraskovsky E., et al. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med. 3:1997;625-631.
18. Roth C., Rochlitz C., Kourilsky P. Immune response against tumors. Adv Immunol. 57:1994;281-351.
19. Pardoll D.M., Topalian S.L. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol. 10:1998;588-594.
20. Mehta-Damani A., Markowicz S., Engleman E.G. Generation of antigen-specific CD8+ CTLs from naive precursors. J Immunol. 153:1994;996-1003.
21. Mehta-Damani A., Markowicz S., Engleman E.G. Generation of antigen-specific CD4+ T cell lines from naive precursors. Eur J Immunol. 25:1995;1206-1211.
22. Ridge J.P., Di Rosa F., Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T- helper and a T-killer cell. Nature. 393:1998;474-478.
23. Guinan E.C., Gribben J.G., Boussiotis V.A., Freeman G.J., Nadler L.M. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood. 84:1994;3261-3282.
24. Dhodapkar M.V., Krasovsky J., Steinman R.M., Bhardwaj N. Mature dendritic cells boost functionally superior CD8(+) T-cell in human without foreign helper epitopes. J Clin Invest. 105:2000;R9-R14.
25. Dhodapkar M.V., Steinman R.M., Sapp M., et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest. 104:1999;173-180.
26. Young J.W., Steinman R.M. Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells. J Exp Med. 171:1990;1315-1332.
27. Gross L. Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res. 3:1943;326-333.
28. Knuth A., Wolfel T., Klehmann E., et al. Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc Natl Acad Sci USA. 86:1989;2804-2808.
29. Fiszer D., Kurpisz M. Major histocompatibility complex expression on human, male germ cells: a review. Am J Reprod Immunol. 40:1998;172-176.
30. Ludewig B., Ochsenbein A.F., Odermatt B., Paulin D., Hengartner H., Zinkernagel R.M. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med. 191:2000;795-804.
31. Nestle F.O., Alijagic S., Gilliet M., et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 4:1998;328-332.
32. Nestle F. Vaccination of melanoma patients with peptide- or tumour lysate-pulsed dendritic cells: a follow-up. 6th International Symposium on Dendritic Cells 2000, Port Douglas, Australia: 46.
33. Mackensen A., Herbst B., Chen J.L., et al. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer. 86:2000;385-392.
34. Thurner B., Haendle I., Roder C., et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 190:1999;1669-1678.
35. Schuler-Thurner B., Dieckmann D., Keikavoussi P., et al. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J Immunol. 165:2000;3492-3496.
36. Valmori D., Gileadi U., Servis C., et al. Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3. J Exp Med. 189:1999;895-906.
37. Lotze M.T., Hellerstedt B., Stolinski L., et al. The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy. Cancer J Sci Am. 3:(Suppl 1):1997;S109-S114.
38. Lotze M, Elder E, Whiteside T et al. Dendritic cell therapy of cancer-not just an antigen presenting cell. 5th International Symposium on Dendritic Cells in Fundamental and Clinical Immunology. 1998, Pittsburgh, PA, USA.
39. Tjoa B.A., Erickson S.J., Bowes V.A., et al. Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate. 32:1997;272-278.
40. Tjoa B.A., Simmons S.J., Bowes V.A., et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate. 36:1998;39-44.
41. Tjoa B.A., Simmons S.J., Elgamal A., et al. Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate. 40:1999;125-129.
42. Murphy G.P., Tjoa B.A., Simmons S.J., et al. Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate. 39:1999;54-59.
43. Murphy G.P., Tjoa B.A., Simmons S.J., et al. Infusion of dendritic cells pulsed with HLA-A2-specific prostate- specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate. 38:1999;73-78.
44. Burch P.A., Breen J.K., Buckner J.C., et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res. 6:2000;2175-2182.
45. Small E.J., Fratesi P., Reese D.M., et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 18:2000;3894-3903.
46. Reichardt V.L., Okada C.Y., Stockerl-Goldstein K.E., Bogen B., Levy R. Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma. Biol Blood Marrow Transplant. 3:1997;157-163.
47. Hsu F.J., Caspar C.B., Czerwinski D., et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood. 89:1997;3129-3135.
48. Reichardt V.L., Okada C.Y., Liso A., et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study. Blood. 93:1999;2411-2419.
49. Lim S.H., Bailey-Wood R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int J Cancer. 83:1999;215-222.
50. Titzer S., Christensen O., Manzke O., et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol. 108:2000;805-816.
51. Hsu F.J., Benike C., Fagnoni F., et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 2:1996;52-58.
52. Kugler A., Stuhler G., Walden P., et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med. 6:2000;332-336.
53. Holtl L., Rieser C., Papesh C., et al. CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer [letter]. Lancet. 352:1998;1358.
54. Holtl L., Rieser C., Papesh C., et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol. 161:1999;777-782.
55. Choudhury A., Gajewski J.L., Liang J.C., et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 89:1997;1133-1142.
56. Eibl B., Ebner S., Duba C., et al. Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the Philadelphia translocation and can induce a CML-specific primary cytotoxic T-cell response. Genes Chromosomes Cancer. 20:1997;215-223.
57. Smit W.M., Rijnbeek M., van Bergen C.A., et al. Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells. Hum Immunol. 53:1997;216-223.
58. Fujii S., Shimizu K., Fujimoto K., et al. Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation. Jpn J Cancer Res. 90:1999;1117-1129.
59. Choudhury A., Toubert A., Sutaria S., et al. Human leukemia-derived dendritic cells: ex-vivo development of specific antileukemic cytotoxicity. Crit Rev Immunol. 18:1998;121-131.
60. Morse M.A., Deng Y., Coleman D., et al. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res. 5:1999;1331-1338.
61. Marchand M., Weynants P., Rankin E., et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3 [letter]. Int J Cancer. 63:1995;883-885.
62. Davis I.D. Cytokine therapy in metastatic renal cancer [letter]. N Engl J Med. 339:1998;850.
63. Nielsen M.B., Marincola F.M. Melanoma vaccines: the paradox of T cell activation without clinical response. Cancer Chemother Pharmacol. 46:(Suppl):2000;S62-S66.
64. Ashley D.M., Faiola B., Nair S., et al. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med. 186:1997;1177-1182.
65. Hart I., Colaco C. Immunotherapy. Fusion induces tumour rejection [news]. Nature. 388:1997;626-627.
66. Nair S.K., Boczkowski D., Morse M., et al. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol. 16:1998;364-369.
67. Philip R., Brunette E., Ashton J., et al. Transgene expression in dendritic cells to induce antigen-specific cytotoxic T cells in healthy donors. Cancer Gene Ther. 5:1998;236-246.
68. Zitvogel L., Fernandez N., Lozier A., et al. Dendritic cells or their exosomes are effective biotherapies of cancer. Eur J Cancer. 35:(Suppl 3):1999;S36-S38.
69. Morse M.A., Coleman R.E., Akabani G., et al. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res. 59:1999;56-58.
70. Thomas R., Chambers M., Boytar R., et al. Immature human monocyte-derived dendritic cells migrate rapidly to draining lymph nodes after intradermal injection for melanoma immunotherapy. Melanoma Res. 9:1999;474-481.
71. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 12:1994;991-1045.
72. Williamson E., Westrich G.M., Viney J.L. Modulating dendritic cells to optimize mucosal immunization protocols. J Immunol. 163:1999;3668-3675.
73. Pulendran B., Smith J.L., Jenkins M., et al. Prevention of peripheral tolerance by a dendritic cell growth factor: flt3 ligand as an adjuvant. J Exp Med. 188:1998;2075-2082.
74. Ellem K.A., Schmidt C.W., Li C.L., et al. The labyrinthine ways of cancer immunotherapy - T cell, tumor cell encounter: "how do I lose thee? Let me count the ways" Adv Cancer Res. 75:1998;203-249.
75. Gabrilovich D.I., Ciernik I.F., Carbone D.P. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol. 170:1996;101-110.